Notes on the design of bioequivalence study: Nirmatrelvir + Ritonavir

Notes on the design of bioequivalence studies with products invited for submission to the WHO Prequalification Team – Medicines (PQT/MED) are issued to aid manufacturers with the development of their product dossier. Deviations from the approach suggested below can be considered acceptable if justified by sound scientific evidence.


Below, additional specific guidance is provided on the invited immediate release products containing nirmatrelvir and ritonavir.

**Pharmacokinetics of nirmatrelvir**

Ritonavir is administered with nirmatrelvir as a pharmacokinetic enhancer or booster resulting in higher systemic concentrations of nirmatrelvir. In healthy volunteers in the fasted state, the mean elimination half-life of a single dose of 150 mg nirmatrelvir administered alone was approximately 2 hours compared to 6-7 hours after administration of a single dose of 250 mg / 100 mg nirmatrelvir / ritonavir.

Less than dose proportional increases in nirmatrelvir exposures were observed after single oral doses of nirmatrelvir ranging from 250 mg to 750 mg (with and without ritonavir 100 mg). Tmax ranged from 2 to 4 h when boosted with ritonavir and from 0.5 to 2 h without ritonavir.

A high fat meal modestly increased the exposure of nirmatrelvir (approximately 15% increase in mean C\text{max} and 1.6% increase in mean AUC\text{0-t}) relative to the fasted state. Consequently, the comparator product can be administered with or without food.

**Pharmacokinetics of ritonavir**

After oral administration, ritonavir peak plasma concentrations are observed after approximately 3–4 hours. Ritonavir is metabolized by the hepatic cytochrome P450 system, primarily by the CYP3A isozyme family and to a lesser extent by the CYP2D6 isoform. Low doses of ritonavir have shown profound effects on the pharmacokinetics of other protease inhibitors (and other products metabolized by CYP3A4), and other protease inhibitors may influence the pharmacokinetics of ritonavir. Ritonavir demonstrates nonlinear pharmacokinetics with greater than dose-proportional increases in AUC. Ritonavir elimination half-life has been reported to be 5 – 6 hours.
Guidance for the design of bioequivalence studies:

Please note that the study design recommendations described below are applicable for applications to PQT/MED in which both the nirmatrelvir and ritonavir components of the proposed co-pack product will be subject to the PQT/MED full assessment pathway. If the proposed co-pack product includes an SRA-approved ritonavir product that is prequalified or seeking prequalification through the abridged assessment route (see PQT/MED website for more information), please note the following:

- The study recommendations below remain unchanged including the requirement to co-administer the proposed ritonavir product with the proposed nirmatrelvir product, however, it is not necessary to measure ritonavir concentrations in the collected plasma samples since bioequivalence will not need to be demonstrated for the ritonavir component.

The recommendations noted above also apply if the proposed co-pack includes a ritonavir product that is already on the current list of prequalified products through the full assessment route.

Taking into account the pharmacokinetic properties of nirmatrelvir and ritonavir, the following guidance with regard to the study design should be taken into account:

**Study design:** A single-dose cross-over design is recommended.

**Dose:** The EoI includes 150 mg tablets of nirmatrelvir and 100 mg tablets of ritonavir. The bioequivalence study should be conducted preferably with the therapeutic dose 2 x 150 mg nirmatrelvir + 1 x 100 mg ritonavir taking into account the less than dose proportional pharmacokinetics of nirmatrelvir.

**Fasted/fed:** As the comparator nirmatrelvir / ritonavir product can be taken with or without food, a fasted state study is recommended.

**Subjects:** Healthy volunteers should be recruited. It is not necessary to include patients in the bioequivalence study.

**Parent or metabolite data for assessment of bioequivalence:** The parent drugs are considered to best reflect the biopharmaceutical quality of the product. Therefore, bioequivalence should be based on the determination of the parent compounds nirmatrelvir and ritonavir.

**Sample size:** Nirmatrelvir pharmacokinetic parameters, $C_{\text{max}}$ and $AUC_{0-t}$, seem to possess moderately high intra-subject variability (22% approximately for $AUC_{0-t}$ and 36% for $C_{\text{max}}$), although available information is limited. Ritonavir pharmacokinetic parameters, $C_{\text{max}}$ and $AUC_{0-t}$, in the fasted state seem to possess moderate variability (25 – 30%), although high variability (>30%) has been observed in some studies. This data may facilitate the calculation of a sufficient sample size for a single-dose cross-over bioequivalence study.

**Washout:** Taking into account the elimination half-life of Nirmatrelvir and ritonavir of 6 – 8 h, a washout period of seven days is considered sufficient to prevent carry over.

**Blood sampling:** The blood sampling should be intensive for the first 4 hours after administration to properly characterize the $C_{\text{max}}$ of nirmatrelvir. It is not necessary to take blood samples beyond 36 hours for the characterization of nirmatrelvir pharmacokinetics. For example, samples can be taken pre-dose and at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.25, 3.50, 3.75, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 24.00 and 36.00 h after drug administration.

**Analytical considerations:** Information currently available to PQT/MED indicates that it is possible to measure nirmatrelvir and ritonavir in human plasma using LC-MS/MS analytical methodology. The bioanalytical method
should be sufficiently sensitive to detect concentrations that are 5% of the $C_{\text{max}}$ in most profiles of each formulation (test or comparator).

**Statistical considerations:** The data for nirmatrelvir and ritonavir should meet the following bioequivalence standards in a single-dose cross-over design study:

- The 90% confidence interval of the relative mean $\text{AUC}_{0-t}$ of the test to reference product should be within 80.00 – 125.00%

- The 90% confidence interval of the relative mean $C_{\text{max}}$ of the test to reference product should be within 80.00 – 125.00%.